Citius Pharmaceuticals (CTXR)
Commercializes LYMPHIR for cutaneous T-cell lymphoma while developing infection, hemorrhoid, and cell-therapy programs.
Something off on this page? Send us feedback.
Commercializes LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma through controlled subsidiary Citius Oncology, while advancing Mino-Lok, Halo-Lido, and a paused cell-therapy platform. Revenue comes from product sales to specialty distributors; the business depends on outsourced manufacturing, commercialization, and a separately traded subsidiary.
Commercializes LYMPHIR, a prescription biologic for adults with relapsed or refractory cutaneous T-cell lymphoma after prior systemic therapy, through majority-owned, separately Nasdaq-listed Citius Oncology. The United States is its core market, while named-patient programs reach parts of Europe, South America, and the Middle East.
Retains development programs in Mino-Lok, an antibiotic catheter-lock solution; Halo-Lido, a topical formulation for hemorrhoid symptoms; and the NoveCite cell-therapy platform, whose work is largely paused. The business develops or acquires products using approved active ingredients or established technologies, aiming for patent or regulatory exclusivity.
Uses a compact internal team alongside outsourced research, manufacturing, and commercial support. LYMPHIR moves through specialty distributors to healthcare providers, hospitals, and infusion centers, making uptake dependent on external manufacturers, distributors, payers, and service partners. Citius Oncology remains a controlled but separately traded subsidiary.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $17.0M · Total debt $7.2M · Total assets $142.3M · Shareholders' equity $66.6M
- Revenue
- $1.5M
- Operating income
- −$11.7M
- Net income
- −$8.9M
No dividends on record.
| Institutions40 holders · as of Mar 31, 2026 | 3.63% | 996.9K shares | |
| Strategic holders1 holder · as of Feb 17, 2026 | 8.72% | 2.39M shares | |
| Otherremainder | 87.65% | 24.06M shares |
27.45M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (27.45M in the company's Sep 3, 2026 report, 11.17M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
CVI Investments, Inc.Strategic | 8.72% | 2.39M | 13Gfiled Feb 17, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.90% | 246,158 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 0.61% | 167,738 | 13Fas of Mar 31, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.28% | 77,755 | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 0.25% | 69,851 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
- Pfizer
CD30-positive CTCL therapy in overlapping specialist treatment pathways.
- Bristol-Myers Squibb
Systemic CTCL therapy after prior treatment.
- Merck
Oral CTCL option for progressive or recurrent disease.
- CorMedix
Catheter-infection prevention overlaps the Mino-Lok buying pathway.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Citius Pharmaceuticals | $0.5800 | −0.84% | $6.5M | — | — | 0.9 | — |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Bristol-Myers Squibb | $67.88 | +0.34% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Merck | $151.86 | +0.15% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| CorMedix | $8.61 | −0.06% | $675.5M | 4.0 | — | 1.5 | +156.5% |
| Median | 26.6 | 10.6 | 2.7 | +5.4% |